{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:03:12Z","timestamp":1791478992951,"version":"4.3.4"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR991872"],"award-info":[{"award-number":["UL1 TR991872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The \u03b2\u2010blockers and antidepressants are two of the most commonly prescribed drug classes in the United States. Several antidepressants are potent inhibitors of cytochrome P450 2D6 liver enzymes (CYP2D6) and can increase the plasma concentrations of certain \u03b2\u2010blockers when administered concomitantly, potentially leading to serious medical consequences such as hypotension, bradycardia, and falls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The primary objective of this investigation was to determine whether initiating an antidepressant in patients receiving \u03b2\u2010blockers increased the risk of hemodynamic adverse events. Our primary outcome was time to hospital admissions or emergency department (ED) visits for an <jats:italic>International Classification of Diseases<\/jats:italic>\u20109 diagnosis suggestive of excessive \u03b2\u2010blockade.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a survival analysis for adults continuously enrolled in the California Medicaid system (Medi\u2010Cal) between 2004 and 2012. Eligible patients were required to be receiving \u03b2\u2010blocker medications that are primarily CYP2D6 substrates (e.g., metoprolol, propranolol, or carvedilol). Univariate and multivariable analyses were performed for patients who concurrently received antidepressants with \u03b2\u2010blockers. An additional multivariable analysis analyzed the association of this combination upon hospitalizations or ED visits for <jats:italic>all causes<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 21,292 beneficiaries met the inclusion criteria, and 4.3% of patients required hospitalization or ED visits within 30\u00a0days of co\u2010medication. In multivariable analysis, patients receiving antidepressants with moderate to strong CYP2D6 inhibitory potential (fluoxetine, paroxetine, duloxetine, or bupropion) had a greater risk for hospitalization or ED visits for hemodynamic events than those initiated on antidepressants with weak CYP2D6 inhibition for 30\u00a0days or less when each was compared with patients receiving no antidepressants (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.03\u20132.81; p=0.04 vs HR 1.24; 95% CI 0.82\u20131.88; p=0.30). Other demographic variables associated with increased morbidity included advanced age, male sex, higher \u03b2\u2010blocker doses, and African American race or Hispanic ethnicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results of this analysis suggest that initiation of certain antidepressants was associated with an increased risk for serious medical sequelae among patients concurrently receiving \u03b2\u2010blockers. Greater risk was observed with antidepressants that potently inhibit the CYP2D6 enzyme, implying that increased morbidity may be mediated by a metabolic drug interaction.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2406","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T03:01:13Z","timestamp":1588042873000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Combining Antidepressants with \u03b2\u2010Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction"],"prefix":"10.1002","volume":"40","author":[{"given":"Jaekyu","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy K.","family":"Hills","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-6441","authenticated-orcid":false,"given":"Patrick R.","family":"Finley","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of California San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db283.htm. Accessed September 4 2018."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.23.3095"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.81"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004000108"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80047-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0b013e3180301b69"},{"key":"e_1_2_7_8_1","unstructured":"National Center for Health Statistics Centers for Disease Control and Prevention (CDC).NHANES Data Documentation Codebook and Frequencies: Prescription Medications.https:\/\/wwwn.cdc.gov\/Nchs\/Nhanes\/2013\u20102014\/RXQ_RX_H.htm. Accessed May 27 2019."},{"key":"e_1_2_7_9_1","unstructured":"KaneS.\u201cClinCalc DrugStats Database.\u201d ClinCalc DrugStats Database. Web. 17 February 2017."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104788"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200702000-00005"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0404-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.7.630"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010365559"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.11.0143"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91265-N"},{"issue":"5","key":"e_1_2_7_17_1","first-page":"244","article-title":"Bradycardia after beginning therapy with metoprolol and paroxetine","volume":"23","author":"K\u00f6nig F","year":"1996","journal-title":"Psychiatr Prax"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.5.595"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390080059014"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125311433580"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200208000-00007"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.43116.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.187"},{"issue":"8","key":"e_1_2_7_24_1","first-page":"970","article-title":"In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R (+)\u2010and S (\u2212)\u2010carvedilol","volume":"25","author":"Oldham HG","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.071811"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.496"},{"key":"e_1_2_7_27_1","unstructured":"FlockhartDA.P450 drug interaction table.http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/table.asp. Accessed February 14 2020."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2004.10.019"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02709-2"},{"key":"e_1_2_7_30_1","volume-title":"AMA Physician ICD\u20109\u2010CM, volumes 1 and 2: International Classification of Diseases, 9th revision clinical modification","author":"American Medical Association","year":"2005"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1319"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.030"},{"key":"e_1_2_7_33_1","unstructured":"Age and sex composition \u2013 2010 Census Bureau.https:\/\/www.census.gov\/prod\/cen2010\/briefs\/c2010br\u201003.pdf. Accessed September 28 2018."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1975.tb03320.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1990.tb03495.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.127111"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00279968"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.103400001"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.216"},{"issue":"4","key":"e_1_2_7_40_1","first-page":"219","article-title":"Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP)","volume":"2","author":"Fletcher A","year":"1988","journal-title":"J Hum Hypertens"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000012546.20194.33"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4422"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.7.1285"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-011-9197-8"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1800"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4200"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.357"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.02.008"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A254"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"e_1_2_7_51_1","unstructured":"California Department of Health Care Services.Medi\u2010Cal certified eligible \u2013 recent trends.www.dhcs.ca.gov. Accessed May 27 2019."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2406","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:35:22Z","timestamp":1761042922000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/phar.2406"],"URL":"https:\/\/doi.org\/10.1002\/phar.2406","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"2020-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}